RFA-PS-25-112: PEP Packs: Postexposure Prophylaxis Packs for Immediate Access to HIV and Sexually Transmitted Infection Prevention
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2024.
Centers for Disease Control and Prevention - ERA offered grants of up to $1.2 million (at least $900,000) to nonprofits, colleges and universities, state and local governments, tribes and businesses. It expected to make one award worth $4.8 million in total. Applications closed on February 19, 2025.
From the official notice on Grants.gov, last changed December 13, 2024. Checked November 7, 2026.
- Award ceiling$1.2 million
- Award floor$900,000
- Total funding$4.8 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | December 13, 2024 |
|---|---|
| Deadline | February 19, 2025 |
| Archived by Grants.gov | March 21, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes and businesses.
All 14 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
N/A
Is this a realistic fit?
- Past Prevention of Disease, Disability, and Death by Infectious Diseases awards averaged $1.9 million; this notice allows up to $1.2 million per award.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to support an implementation research study. In this study, optimal strategies will be assessed for a postexposure prophylaxis (PEP) in pocket (PiP) approach for prevention of HIV and sexually transmitted infections (STIs) among disproportionately affected populations, for example, gay, bisexual, and other men who have sex with men (MSM) and transgender women (TGW). The recipient will implement and evaluate a comprehensive strategy to integrate PEP packs as a component of existing PrEP and STI clinical services. PEP packs will include a supply of antiretroviral medication for nonoccupational PEP (nPEP), doxycycline for STI PEP (DoxyPEP), HIV and STI self-test kits, and instruction materials. Study clinics should be in communities with high rates of HIV diagnoses among disproportionately affected populations, for example, Black and Hispanic MSM and TGW.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death by Infectious Diseases (93.084) awarded $241 million across 128 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Puerto Rico Science, Technology, and Research Trust | Puerto Rico | 4 | $14.5 million |
| Massachusetts Department of Public Health | Massachusetts | 1 | $11.6 million |
| Emory University | Georgia | 3 | $11.5 million |
| Uganda Virus Research Institute | 1 | $8.7 million | |
| Ponce Medical School Foundation Inc | Puerto Rico | 2 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-PS-25-112 still open?
No. It closed on February 19, 2025. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for PEP Packs: Postexposure Prophylaxis Packs for Immediate Access to HIV and Sexually Transmitted Infection Prevention?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for PEP Packs: Postexposure Prophylaxis Packs for Immediate Access to HIV and Sexually Transmitted Infection Prevention?
Closed February 19, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.2 million each. About $4.8 million in total for one award.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before?
The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)